PILOT STUDY OF THE EFFECT OF A SUBSTANCE P ANTAGONIST, APREPITANT, ON THE SECRETION OF ALDOSTERONE IN PATIENTS WITH OBSTRUCTIVE SLEEP APNEA AND ARTERIAL HYPERTENSION SYNDROME - (APHOS3)

Status

Not yet recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-514837-39-00

Acronym

2020/0431/HP

Enrollment

Registered

2024-07-01

Start date

Unknown

Completion date

Unknown

Last updated

2024-07-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with obstructive sleep apnea syndrome with arterial hypertension

Brief summary

24-hour aldosteronuria measurements. At the beginning and end of each treatment period.

Detailed description

blood pressure measurements, aldosteronemia, reninemia, plasma and urinary electrolytes, 24-hour plasma and urinary cortisol, plasma ACTH. At the beginning and end of each treatment period.

Interventions

DRUGLACTOSE MONOHYDRATE

DRUGEMEND 125 mg+80 mg hard capsules

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
24-hour aldosteronuria measurements. At the beginning and end of each treatment period.	—

Secondary

Measure	Time frame
blood pressure measurements, aldosteronemia, reninemia, plasma and urinary electrolytes, 24-hour plasma and urinary cortisol, plasma ACTH. At the beginning and end of each treatment period.	—

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026